- Antibiotics for community-acquired lower respiratory tract infections secondary to Mycoplasma pneumoniae in children
- Antibiotics for community‐acquired pneumonia in adult outpatients
- Antibiotics for community‐acquired pneumonia in children
- Antibiotics for exacerbations of asthma
- Antibiotics for exacerbations of chronic obstructive pulmonary disease
- Antibiotics for persistent nasal discharge (rhinosinusitis) in children
- Antibiotics for preterm rupture of membranes
- Antibiotics for prolonged wet cough in children
- Antibiotics for the common cold and acute purulent rhinitis
- Antibiotics for treating community‐acquired pneumonia in people with sickle cell disease
- Antibiotics for treatment of sore throat in children and adults
- Antibiotics for ureaplasma in the vagina in pregnancy
- Antibiotics for whooping cough (pertussis)
- Antibiotics to reduce post‐tonsillectomy morbidity
- Anticholinergic agents for chronic asthma in adults
- Anticholinergic bronchodilators versus beta2‐sympathomimetic agents for acute exacerbations of chronic obstructive pulmonary disease
- Anticholinergic drugs for wheeze in children under the age of two years
- Anticholinergic therapy for acute asthma in children
- Anticholinergic therapy for bronchiectasis
- Anticholinergic therapy for chronic asthma in children over two years of age
The Cochrane Database of Systematic Reviews is considered the gold standard for evidence-based medicine. Essential Evidence Plus includes the latest and most up-to-date summaries of systematic reviews from the Cochrane Library, which are the most rigorous and reliable evaluations of medical therapies available. You’ll find summarized evaluations of the world’s best literature on the effectiveness of therapy for 3,300+ clinical problems.